Single-Dose, Dose-Escalation Study With LY3303560 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2018
At a glance
- Drugs LY 3303560 (Primary) ; LY 3303560 (Primary)
- Indications Alzheimer's disease; Cognition disorders
- Focus Adverse reactions; First in man
- Sponsors Eli Lilly
- 01 Feb 2018 Planned End Date changed from 1 May 2018 to 1 Jul 2018.
- 01 Feb 2018 Planned primary completion date changed from 1 May 2018 to 1 Jul 2018.
- 01 Feb 2018 Status changed from recruiting to active, no longer recruiting.